Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648. // Annals of Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S0923753426014559?dgcid=rss_sd_all
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648. Annals of Oncology. https://www.sciencedirect.com/science/article/pii/S0923753426014559?dgcid=rss_sd_all
“Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648.” Annals of Oncology.
@article{article35963,
title = {Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648},
journal = {Annals of Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S0923753426014559?dgcid=rss_sd_all}
}